ARCELLX, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • December 28th, 2021 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledDecember 28th, 2021 Company Industry JurisdictionThis Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Arcellx, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
LEASE BETWEEN ARCELLX, INC., AS TENANT AND TFG WEST WATKINS PROPERTY, LLC, AS LANDLORD 25, 35 & 45 WEST WATKINS MILL ROAD GAITHERSBURG, MARYLANDLease Agreement • December 28th, 2021 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Maryland
Contract Type FiledDecember 28th, 2021 Company Industry JurisdictionTHIS LEASE is dated as of October 5th, 2018 (the “Execution Date”) between the Landlord and the Tenant named below, and is of space in the Building described below.
ARCELLX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT MARCH 26, 2021Investors’ Rights Agreement • December 28th, 2021 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledDecember 28th, 2021 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 26th day of March 2021, by and among Arcellx, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (together with any subsequent investors or transferees, who become parties to this Agreement in accordance with Section 6.9 hereof, each an “Investor” and together the “Investors”).
DEVELOPMENT, EVALUATION AND LICENSE AGREEMENT between PFENEX INC. and ARCELLX, INC. Dated as of December 24, 2018Development, Evaluation and License Agreement • December 28th, 2021 • Arcellx, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledDecember 28th, 2021 Company IndustryThis DEVELOPMENT, EVALUATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 24, 2018 (the “Effective Date”) by and between Pfenex Inc., a Delaware corporation, with its principal place of business at 10790 Roselle Street, San Diego, CA 92121 (“Pfenex”), and Arcellx, Inc., a Delaware corporation, with its principal place of business at 20271 Goldenrod Lane, Suite 2099, Germantown, MD 20876 (“Arcellx”). Pfenex and Arcellx are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.